IMNN · Imunon, Inc.
$1.24
-0.04 (-3.13%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Such conditions raise substantial doubts about the Company's ability to continue as a going concern. Based on the above, management has determined there is substantial doubt regarding our ability to continue as a going concern.”View the 10-Q filed Aug 11, 2026
Market Cap
$7.91M
Shares
5.61M
Volume · Oct 5
82.72K
Avg daily vol (3M)
150.84K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.24
Open$1.30
Day$1.22–1.32
52W close$1.24–5.33
Avg vol 30d125K
Short int194K · 3.5% float · 1.3d
Short vol38%
Last earningsAug 11, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 11
Up next
Next earnings call
Nov 15, 2026
Est · unconfirmed
· in 6 wks
filed Aug 11, 2026
call held Aug 11, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$500,000
Trailing 12 months
Net income (TTM)
−$14.72M
Trailing 12 months
Revenue growth YoY
+0.0%
Year over year
Operating margin
-4,984.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+309.7%
Year over year · more shares
Price change (1Y)
-76.5%
Trailing year
Short interest
3.5%
Latest settlement · 1.3 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−50%
below
Price vs 50-day avg
−18%
below
RSI (14)
33
neutral
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−22%
trailing
6-month return
−60%
trailing
YTD return
−67%
this year
Relative strength
−72%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+21% holders QoQ · +6 funds added
Insider flow
Distributing
Net -$15.7K over 90 days · 100% sells
Short interest
Rising
3.45% of float · ▲ +114.2% MoM · 1.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
23 holders — mid 3-yr range
Squeeze score
54
elevated · 0–100
Fundamentals
Revenue growth
0%
Y/Y
EPS growth
+60%
Y/Y
Free cash flow
$-14.2M
Balance sheet
$5.5M
net cash
Quant / Vol
risk profile
Volatility
53%
annualized · 1-yr
Max drawdown
−77%
past year
ATR
9.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 14, 2020
Anticipated savings over the next 18 months compared to our budg
· next 18 months
$8M – $9M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−50%
Bearish
Price vs 50-day avg
−18%
Bearish
RSI (14)
33
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+21% holders QoQ · +6 funds added
Insider flow
Distributing
Net -$15.7K over 90 days · 100% sells
Short interest
Rising
3.45% of float · ▲ +114.2% MoM · 1.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
23 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 0%
Range high $5
vs 200-day avg -50%
vs 50-day avg -18%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IMNN
this stock
Imunon, Inc.
|
$7.91M | -67.5% | +0.0% | — | 3.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IMNN | -10.1% | -21.5% | -60.0% | -3.9% | -67.5% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -11.3% | -22.1% | -71.6% | -5.5% | -81.1% |